The altruistic donation of BM or PBMCs by members of the general public has permitted the establishment of unrelated donor SCT as an effective treatment modality in high-risk leukaemia and other haematological malignancies. Over the past three decades, the application of fundamental advances in stem cell and transplant biology have underpinned major improvements in patient outcome, but many patients transplanted using unrelated donor stem cells are still destined to die of transplant toxicity or disease relapse. Despite this, clinical trials in unrelated donor transplantation remain a relative rarity and most patients are not transplanted in the context of either an early-or late-phase clinical study. There is therefore an urgent need to prioritize clinical trials in unrelated donor transplantation and the report by King et al. on behalf of the World Marrow Donor Association (WMDA) is timely.
Although it is natural to assume that individuals who have already displayed the selflessness required to proceed with stem cell donation will be minded to approve of research projects directly involving themselves or their harvested product, it would be wrong to assume this. In this context, the standards and guidelines published by the WMDA which clarify how the Declaration of Helsinki's principles should apply to volunteer unrelated donors and their donated stem cell products will be of value to transplant registries and researchers alike. It is particularly important to remember that donors may find it difficult to decline participation in additional research studies addressing the process of stem cell donation and it is of the utmost importance that these are presented in 'as un-coercive a manner as possible'. The other major area of research activity related to unrelated donor transplantation pertains to clinical studies performed on transplant recipients with the aim of improving patient outcome. Such trials only require patient consent and there is no obligation to inform either the donor or the Registry regarding the patient's recruitment to a clinical study. However, in light of the motivational influences felt by unrelated donors, consideration should be given to whether they might wish to know that their stem cell donation is being utilized in the context of an ethically approved clinical trial designed to improve patient outcome. Furthermore, national registries may feel it timely to debate to what extent their obligation to the donor might include the facilitation of early-and late-phase clinical studies in unrelated transplantation so that the benefits of these myriad individual acts of kindness can be maximized for current and future generations.
